790 likes | 874 Views
Novel Autoregulatory Function of HBV M Protein on Surface Gene Expression. 成大醫學院 病理科 分子病理實驗室 分子診斷實驗室 呂政展. Risk Factors of Hepatocellular Carcinoma. Infection by hepatitis B and C viruses (70% caused by HBV in Taiwan ) Cirrhosis of any etiology
E N D
Novel Autoregulatory Function of HBV M Protein on Surface Gene Expression 成大醫學院 病理科 分子病理實驗室 分子診斷實驗室 呂政展
Risk Factors of Hepatocellular Carcinoma • Infection by hepatitis B and C viruses (70% caused by HBV in Taiwan) • Cirrhosis of any etiology • Primary hemochromatosis (excessive accumulation of iron in the liver and pancrea) • Prolonged exposure to Aflatoxin B1 (cause a specific mutation in p53)
Natural History of Chronic HBV Infection Science 262: 369, 1993
At non-replicative stage of the natural course of HBV infection, e Ag conversion is often associated with selection of preS2-defective mutant and HBV integration • Groundglass hepatocytes, a hallmark of chronic HBV infection, within cirrhotic nodule frequently overexpress L protein. These groundglass-appearance hepatocytes harbor mutations within the preS2 regions
Overexpression of LHBsAg and HCC • Expression of Hepatitis B Virus Large Envelope Polypeptide Inhibits Hepatitis B Surface Antigen Secretion in Transgenic Mice (J Virol 60: 880, 1986) • Structural and Pathological Effects of Synthesis of Hepatitis B Virus Large Envelope Polypeptide in Transgenic Mice (Proc Natl Acad Sci, USA 84: 6909, 1987) • Molecular Pathogenesis of Hepatocellular Carcinoma in Hepatitis B Virus Transgenic Mice (Cell 59: 1145, 1989)
Structural and Pathological Effects of Synthesis of Hepatitis B Virus Large Envelope Polypeptide in Transgenic Mice (Proc Natl Acad Sci, USA 84: 6909, 1987) • Mouse albumin promoter-not preS1 promoter • HBsAg accumulation develop hepatocellular injury that initiates a programmed response characterized by inflammation, regenerative hyperplasia, transcriptional deregulation, and aneuploidy.
HBx gene of hepatitis B virus induces liver cancer in transgenic mice (Nature 351: 317, 1991) • HBx gene under its own regulatory element
Phylogenetic Tree of Hepadnaviruses GS: ground squirrels
Different S Ag Expression Patterns during Chronic HBV Infection A.Membranous form; B, Diffuse cytoplasmic form; C. Inclusion-like form; D. Marginal form (monoclonal antibody against “a” determinant Fan et al, 2000
Different S Ag Expression Patterns during Chronic HBV Infection A.Membranous form; B, Diffuse cytopplasmic form; C. Inclusion-like form; D. Marginal form (preS1 monoclonal antibody) Fan et al, 2000
* C Terminal protein Spacer DNA polymerase RNaseH X pre-S1 -S2 S
Structural Relationships Among Large, Middle, and Small (Major) Surface Proteins 100 bp pre-S1 pre-S2 S 119 55 226 S M L
Differential Regulation of Synthesis of HBV Surface Proteins • One virion contains 300-400 small(S) surface protein and 40-80 middle (M) and large (L) surface proteins • S surface transcripts/Ag: L surface transcripts/Ag: = 5~10:1 • Balanced synthesis of various forms is critical for virus life cycle
preS1 S promoter 3213 157 2856 833 preS1 preS2 S ATG ATG ATG Small Middle Large
Puzzling Facts about preS1 and S Promoters in Reporter Gene Assay • In reporter gene assay, the isolated preS1 and S promoters have similar strength • In infected livers and and transfection experiments, the preS1 transcript is about 1/10 of S transcript
Linker-Scanning of S Gene PromotersPrimer extension analysis Wt 1 2 3 4 5 6 7 8 9 10 11 12 13
S promoter sequence and transcriptional factor binding sites 3050 AAGGCTCACCCCTCCACACGGCGGTATTTTGGGGTGGAGCCCTCAGGCTCAGGGCATATTG ACCACAGTGTCAACAATTCCTCCTCCTGCCTCCACCAATCGGCAGTCAGGAAGGCAGCCTAC TCCCATCTCTCCACCTCTAAGAGACAGTCATCCTCAGGCCATGCAGTGGAATTCCACTGCCTT CCACCAAACTCTGCAGGATCCCAGAGTCAGGGGTCTGTATCTTCCTGCTGGTGGCTCCAGTT Sp1 3111 Sp1 CBF CAF Sp1 3173 Middle S Sp1 15
Linker Scanning of S promoter for Elements regulating L protein expression
CCAAT-box Mutation on L protein Expression in HBV Whole and Subgenomic Fragment Circular HBV DNA
Surface Gene Mutants Constructs Pre-S2 S Pre-S1 WT 2856 3213 157 1 3042 3113 * ATG ATA 2 6 59 3 3154 24 4 3194 5 * ATG AGG 5 6 2948 3090 3-1 9 63 Ls3 ACCAATCGGC GGTGACCTAA 3144 3153
HBV Mutants Associated with HCC Pre-S2 S Pre-S1 WT 2856 3213 157 1 3042 3113 * ATG ATA 2(6-59)Del 2 6 59 2Int 3 3154 24 4 3194 5 * ATG AGG 5 6 2948 3090 3-1 9 63 Ls3 ACCAATCGGC GGTGACCTAA 3144 3153
Western blot of HBsAg protein Pre-S2 S Pre-S1 2_6-59 2856 3213 157 * ATG ATA 2_int 2856 3213 157 2_6-59 2_int WT PreS ( 0.24X, 2.2X ) S ( 1.2X, 0.23X ) αtubulin
Clinical observations from chronically HBV-infected patients indicate that expression of M protein is a marker of chronicity, implying that expression of M protein is indicative of active viral replication (Kurai et al., 1989)
Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier Virology 194:137-148, 1993
From HhH-7 cells Transfected with mutated preS2 in S3 HBV virion from serum of infected patients
Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis (Hepatology 26:495-499, 1997) • ﹟38-year-old surgeon was HBsAg(+) in the absence of other serological HBV markers (accidental exposure to possibly infected blood?); IgM anti-HBc, anti-HBe, ALT: 4990, 10 day later this patient dies of a hyper acute form of type B FH • About 7 weeks after the death of this patient, his mother developed a fever and asthenia. She spoke of exposure to the blood of her son after an accidental needle-stick the day before the son’s hospitalization.
L(LHBs) M(MHBs) S(SHBs) S pre-S1 pre-S2 p(3A)SAg (WT) 2856 3213 157 * ATG ATA p(3A)SAg/Mint
3.0 p(3A)SAg/Mint p(3A)SAg (WT) 2.5 2.2X 2.0 Relative level L 1.5 M 1.0 S 0.5 0.23X 0 0.0 α-tubulin WT Mint WT Mint WT Mint L S M
Primer extension analysis p(3A)SAg/Mint p(3A)SAg (WT) 3.0 b-gal 2.35X 2.5 2.0 LHBs Relative level 1.5 1.0 MHBs 0.5 0 0.12X 0.0 Mint WT Mint WT WT Mint SHBs L M S
Sequence of the preS1 and S promoter region HNF1 Oct1 HNF3 Sp1 2721 AGGTAGTTAATCATTACTTCCAAACCAGACATTATTTACATACTCTTTGGAAGGCTGGTAT TCTATATAAGCGGGAAACCACACGTAGCGCATCATTTTGCGGGTCACCATATTCTTGGGAA CAAGAGCTACAGCATGGGAGGTTGGTCATCAAAACCTCGCAAAGGCATGGGGACGAATCTT TCTGTTCCCAATCCTCTGGGATTCTTTCCCGATCATCAGTTGGACCCTGCATTCGGAGCCA ACTCAAACAATCCAGATTGGGACTTCAACCCCGTCAAGGACGACTGGCCAGCAGCCAACCA AGTAGGAGTGGGAGCATTCGGGCCAAGGCTCACCCCTCCACACGGCGGTATTTTGGGGTGG AGCCCTCAGGCTCAGGGCATATTGACCACAGTGTCAACAATTCCTCCTCCTGCCTCCACCA ATCGGCAGTCAGGAAGGCAGCCTACTCCCATCTCTCCACCTCTAAGAGACAGTCATCCTCA GGCCATGCAGTGGAATTCCACTGCCTTCCACCAAACTCTGCAGGATCCCAGAGTCAGGGGT CTGTATCTTCCTGCTGGTGGCTCCAGTTCAGGAACAGTAAACCCTGCTCCGAATATTGCCTCT 2782 TBP 2843 Large S 2904 HNF1 2965 Sp1 3026 Sp1 NF-Y 3087 CAF Sp1 Sp1 3148 3209 Middle S 49
2438 156 HBV Luciferase reporter gene 3’ 5’ nt 2438 nt 2855 nt 3114 nt 156 ATG ATG preS2 preS1 pPreS1-Luc pS-Luc Fig 2A
1.4 1.2 1.0 Relative luciferase 0.8 activity 0.6 0.4 0.2 0.0 - - - - + ( 0.5 ) pGL3-basic ( mg ) - + + + + ( 0.5 ) pPreS1-Luc - - P(3A)S(Pst)/Sint 0.1 0.2 0.4 - 0.3 pTZ19U 0.4 0.4 0.2 Fig 2B
7 6 5 Relative luciferase activity 4 3 2 1 0 - - - - + ( 0.5 ) Vector ( mg ) - + + + + ( 0.5 ) pS-Luc - - p(3A)S(Pst)/Sint 0.1 0.2 0.4 - 0.3 pTZ19U 0.4 0.4 0.2 Fig 2C
3.0 2.5 2.0 Relative luciferase activity 1.5 1.0 0.5 0.0 - - - - + ( 0.5 ) Vector ( mg ) - + + + + ( 0.5 ) pS-Luc - - pCMV-MHBs 0.1 0.2 0.4 - pCMV-Basic 0.3 0.4 0.4 0.2 Fig 2D
7 6 5 Relative luciferase activity 4 3 2 1 0 X - - - - + pGL3-Basic ( mg ) - + + + + pS-Luc - - pCMV-preS2 0.1 0.2 0.4 - pCMV-Basic 0.3 0.4 0.4 0.2
preS2 S * 55 226 ATG AGG pCMV-MHBs/Sint a.a 1- 152 pCMV-MHBs1-152 a.a 1- 76 pCMV-MHBs1-76 a.a 1- 71 pCMV-MHBs1-71 a.a 1- 57 pCMV-MHBs1-57 a.a 1- 55 pCMV-PreS21-55 pCMV-PreS21-52 a.a 1- 52 a.a 1- 48 pCMV-PreS21-48 pCMV-PreS21-47 a.a 1- 47 a.a 5 - 55 pCMV-PreS25-55 a.a 16 - 55 pCMV-PreS216-55 a.a 19 - 55 pCMV-PreS219-55 Fig. 3A
5.0 4.5 4.0 3.5 3.0 Relative luciferase activity 2.5 2.0 1.5 1.0 0.5 0.0 2 3 4 5 6 7 8 9 10 11 12 13 14 1 - - - - - - - - - - - - ( mg ) - + (0.5) pGL3-Basic - + + + + + + + + + + + + + pS-Luc (0.5) - - - - - - - pCMV-MHBs/Sint - - - - - - 0.4 - - - - - - - - - - - - - 0.4 pCMV-MHBs1-152 - - - - - - - - - - - - - 0.4 pCMV-MHBs1-76 - - - - - - - - - - - - - pCMV-MHBs1-71 0.4 - - - - - - - - - - - - - 0.4 pCMV-MHBs1-57 - - - - - - - - - - - - - 0.4 pCMV-preS21-55 - - - - - - - - - - - - - 0.4 pCMV-preS21-52 - - - - - - - - - - - - - 0.4 pCMV-preS21-48 - - - - - - - - - - - - - 0.4 pCMV-preS21-47 - - - - - - - - - - - - - 0.4 pCMV-preS25-55 - - - - - - - - - - - - - 0.4 pCMV-preS216-55 - - - - - - - - - - - - - 0.4 pCMV-preS219-55 Fig. 3B - - - - - - - - - - - - pCMV-Basic 0.4 0.4
Results • Deletion mapping experiments indicate that maximal transactivating region coincides with preS2 domain